122 related articles for article (PubMed ID: 31570278)
1. Potential role of TET2 in gastric cancer cisplatin resistance.
Zhou K; Guo H; Zhang J; Zhao D; Zhou Y; Zheng Z; Xu Y; Li Y; Wang D
Pathol Res Pract; 2019 Nov; 215(11):152637. PubMed ID: 31570278
[TBL] [Abstract][Full Text] [Related]
2. Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling.
Fu D; Wang C; Yu L; Yu R
Cell Mol Biol Lett; 2021 Jun; 26(1):26. PubMed ID: 34098867
[TBL] [Abstract][Full Text] [Related]
3. TXNL1 induces apoptosis in cisplatin resistant human gastric cancer cell lines.
Ni P; Xu W; Zhang Y; Chen Q; Li A; Wang S; Xu S; Zhou J
Curr Cancer Drug Targets; 2015; 14(9):850-9. PubMed ID: 25348020
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling.
Ni Q; Zhang Y; Tao R; Li X; Zhu J
Aging (Albany NY); 2021 Mar; 13(6):8665-8687. PubMed ID: 33714198
[TBL] [Abstract][Full Text] [Related]
5. miR-149 reverses cisplatin resistance of gastric cancer SGC7901/DDP cells by targeting FoxM1.
Li X; Liang J; Liu YX; Wang Y; Yang XH; Luan BH; Zhang GL; Du J; Wu XH
Pharmazie; 2016 Nov; 71(11):640-643. PubMed ID: 29441968
[TBL] [Abstract][Full Text] [Related]
6. miR‑138‑5p modulates the expression of excision repair cross‑complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin.
Ning J; Jiao Y; Xie X; Deng X; Zhang Y; Yang Y; Zhao C; Wang H; Gu K
Oncol Rep; 2019 Feb; 41(2):1131-1139. PubMed ID: 30535472
[TBL] [Abstract][Full Text] [Related]
7. LncRNA SNHG5 promotes cisplatin resistance in gastric cancer via inhibiting cell apoptosis.
Li M; Zhang YY; Shang J; Xu YD
Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4185-4191. PubMed ID: 31173289
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells.
Wang M; Zhang R; Zhang S; Xu R; Yang Q
Gene; 2019 Jun; 700():110-119. PubMed ID: 30917930
[TBL] [Abstract][Full Text] [Related]
9. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7.
Zhou X; Jin W; Jia H; Yan J; Zhang G
J Exp Clin Cancer Res; 2015 Mar; 34(1):28. PubMed ID: 25888377
[TBL] [Abstract][Full Text] [Related]
10. miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD.
Zhu M; Zhou X; Du Y; Huang Z; Zhu J; Xu J; Cheng G; Shu Y; Liu P; Zhu W; Wang T
Mol Med Rep; 2016 Aug; 14(2):1742-50. PubMed ID: 27357419
[TBL] [Abstract][Full Text] [Related]
11. Increase in CIP2A expression is associated with cisplatin chemoresistance in gastric cancer.
Ji J; Zhen W; Si Y; Ma W; Zheng L; Li C; Zhang Y; Qin S; Zhang T; Liu P; Zheng X; Liu Y
Cancer Biomark; 2018 Feb; 21(2):307-316. PubMed ID: 29103022
[TBL] [Abstract][Full Text] [Related]
12. [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):404-11. PubMed ID: 26463141
[TBL] [Abstract][Full Text] [Related]
13. miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Gu Y; Fei Z; Zhu R
Anticancer Drugs; 2020 Apr; 31(4):385-393. PubMed ID: 31913198
[TBL] [Abstract][Full Text] [Related]
14. TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer.
Xu W; Wang S; Chen Q; Zhang Y; Ni P; Wu X; Zhang J; Qiang F; Li A; Røe OD; Xu S; Wang M; Zhang R; Zhou J
Cell Death Dis; 2014 Feb; 5(2):e1055. PubMed ID: 24525731
[TBL] [Abstract][Full Text] [Related]
15. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
Yang M; Shan X; Zhou X; Qiu T; Zhu W; Ding Y; Shu Y; Liu P
Anticancer Agents Med Chem; 2014; 14(6):884-91. PubMed ID: 24875127
[TBL] [Abstract][Full Text] [Related]
16. RNF138 confers cisplatin resistance in gastric cancer cells via activating Chk1 signaling pathway.
Lu Y; Han D; Liu W; Huang R; Ou J; Chen X; Zhang X; Wang X; Li S; Wang L; Liu C; Miao S; Wang L; Ma C; Song W
Cancer Biol Ther; 2018; 19(12):1128-1138. PubMed ID: 30260263
[TBL] [Abstract][Full Text] [Related]
17. PEITC reverse multi-drug resistance of human gastric cancer SGC7901/DDP cell line.
Tang T; Song X; Liu YF; Wang WY
Cell Biol Int; 2014 Apr; 38(4):502-10. PubMed ID: 23956061
[TBL] [Abstract][Full Text] [Related]
18. MiR-876-3p regulates cisplatin resistance and stem cell-like properties of gastric cancer cells by targeting TMED3.
Peng C; Huang K; Liu G; Li Y; Yu C
J Gastroenterol Hepatol; 2019 Oct; 34(10):1711-1719. PubMed ID: 30843262
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2.
Xu HB; Shen FM; Lv QZ
Eur J Pharmacol; 2015 Dec; 769():1-7. PubMed ID: 26407653
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of c-Myc by let-7b mimic reverses mutidrug resistance in gastric cancer cells.
Yang X; Cai H; Liang Y; Chen L; Wang X; Si R; Qu K; Jiang Z; Ma B; Miao C; Li J; Wang B; Gao P
Oncol Rep; 2015 Apr; 33(4):1723-30. PubMed ID: 25633261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
